R. Schwartz

发表

The transient expression of CHIKV VLP in large stirred tank bioreactors

Peifeng Chen, Jacob Demirji, Vera B. Ivleva, 2019, Cytotechnology.

Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection

J. Mascola, E. Boritz, T. Chun, 2015, Science Translational Medicine.

Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV‐1 human monoclonal antibody VRC01 in healthy adults

J. Mascola, R. Koup, R. Bailer, 2015, Clinical and experimental immunology.

Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials

J. Mascola, T. Pierson, C. Andrews, 2017, The Lancet.

Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults

J. Mascola, A. Namboodiri, R. Koup, 2018, PLoS medicine.

Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial

J. Mascola, D. Baltimore, E. Boritz, 2022, Nature Medicine.

Safety and pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: a phase 1 dose-escalation clinical trial.

J. Mascola, A. Namboodiri, R. Koup, 2019, The lancet. HIV.

Comprehensive Flow Cytometry Analysis of PEI-Based Transfections for Virus-Like Particle Production

Vera B. Ivleva, J. Horwitz, R. Schwartz, 2020, Research.

Cloning and assessment of tumorigenicity and oncogenicity of a Madin-Darby canine kidney (MDCK) cell line for influenza vaccine production.

D. Tabor, R. Schwartz, L. Richman, 2010, Vaccine.

Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial

J. Mascola, T. Pierson, R. Koup, 2014, The Lancet.

Delivery of Human Immunodeficiency Virus Vaccine Vectors to the Intestine Induces Enhanced Mucosal Cellular Immunity

G. Nabel, M. Kanekiyo, J. Gall, 2009, Journal of Virology.

Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial.

J. Mascola, R. Bailer, B. Graham, 2021, The Lancet. Respiratory medicine.

Development of a High Yielding Bioprocess for a Pre-fusion RSV Subunit Vaccine.

E. Carey, Peifeng Chen, J. Horwitz, 2020, Journal of Biotechnology.

A proof of concept for structure-based vaccine design targeting RSV in humans

J. Mascola, P. Kwong, B. Graham, 2019, Science.

Current challenges in implementing cell-derived influenza vaccines: implications for production and regulation, July 2007, NIBSC, Potters Bar, UK.

R. Schwartz, O. Engelhardt, J. Heldens, 2009, Vaccine.

Correction: Decreased Pre-existing Ad5 Capsid and Ad35 Neutralizing Antibodies Increase HIV-1 Infection Risk in the Step Trial Independent of Vaccination

S. Buchbinder, M. McElrath, G. Nabel, 2012, PLoS ONE.

Decreased Pre-existing Ad5 Capsid and Ad35 Neutralizing Antibodies Increase HIV-1 Infection Risk in the Step Trial Independent of Vaccination

S. Buchbinder, M. McElrath, G. Nabel, 2012, PloS one.

Phase 2 evaluation of parainfluenza type 3 cold passage mutant 45 live attenuated vaccine in healthy children 6-18 months old.

R. Karron, B. Murphy, William Rodriguez, 2004, The Journal of infectious diseases.

A Micro-Polyethylene Glycol Precipitation Assay as a Relative Solubility Screening Tool for Monoclonal Antibody Design and Formulation Development.

S. Joshi, D. Volkin, R. Schwartz, 2016, Journal of pharmaceutical sciences.

Characterization of N-glycosylation profiles from mammalian and insect cell derived chikungunya VLP.

R. Rustandi, R. Schwartz, D. Casimiro, 2016, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

A serum-free Vero production platform for a chimeric virus vaccine candidate

R. Schwartz, Inn H. Yuk, Richard M. Schwartz, 2006, Cytotechnology.

Optimization of the Solubility of HIV-1-Neutralizing Antibody 10E8 through Somatic Variation and Structure-Based Design

B. Haynes, D. Ho, J. Mascola, 2016, Journal of Virology.

A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA.

Edward Wright, Thomas Strecker, Paul Chaplin, 2015, The New England journal of medicine.

Chimpanzee Adenovirus Vector Ebola Vaccine

J. Mascola, R. Cortese, A. Nicosia, 2017, The New England journal of medicine.

Development of a stable virus-like particle vaccine formulation against Chikungunya virus and investigation of the effects of polyanions.

C Russell Middaugh, Sangeeta B Joshi, David B Volkin, 2013, Journal of pharmaceutical sciences.

Use of MDCK cells for production of live attenuated influenza vaccine.

R. Schwartz, G. Kemble, Jonathan Liu, 2009, Vaccine.

An avian influenza H7 DNA priming vaccine is safe and immunogenic in a randomized phase I clinical trial

J. Mascola, R. Koup, R. Bailer, 2017, npj Vaccines.

DNA Priming for Seasonal Influenza Vaccine: A Phase 1b Double-Blind Randomized Clinical Trial

R. Koup, D. Bernstein, Shital M. Patel, 2015, PloS one.

Phase 1 Study of Pandemic H1 DNA Vaccine in Healthy Adults

J. Mascola, R. Koup, G. Nabel, 2015, PloS one.

Development of a mammalian cell culture process for rapid Clinical-Scale production of novel Influenza Nanoparticle vaccines

R. Schwartz, Payal Biswas, James Lee, 2015, BMC Proceedings.

Structural Characterization and Formulation Development of a Trivalent Equine Encephalitis Virus-Like Particle Vaccine Candidate.

S. Joshi, D. Volkin, R. Schwartz, 2018, Journal of pharmaceutical sciences.

Effect of a Chikungunya Virus-Like Particle Vaccine on Safety and Tolerability Outcomes: A Randomized Clinical Trial.

J. Mascola, T. Pierson, R. Koup, 2020, JAMA.